Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Binder

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Transplantation and Cellular Therapy|August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction TherapyMohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Blood Advances|May 23, 2020
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Rhett P Ketterling, et al.
Blood Cancer Journal|September 29, 2025
Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomesTamer Hellou, Daniel G Packard, Suheil Albert Atallah-Yunes, et al.
Blood Advances|December 4, 2024
Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory responseWazim Mohammed Ismail, Jenna A Fernandez, Moritz Binder, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
American Journal of Hematology|June 4, 2026
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell LeukemiaDaniel G Packard, Shaji K Kumar, Angela Dispenzieri, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Blood Advances|April 9, 2026
Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL AmyloidosisMaximilian Johannes Steinhardt, Eli Muchtar, Taxiarchis V Kourelis, et al.
Blood Cancer Journal|June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myelomaBinoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
Haematologica|March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasoneRicardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Transplantation and Cellular Therapy|August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction TherapyMohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Blood Advances|May 23, 2020
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Rhett P Ketterling, et al.
Blood Cancer Journal|September 29, 2025
Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomesTamer Hellou, Daniel G Packard, Suheil Albert Atallah-Yunes, et al.
Blood Advances|December 4, 2024
Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory responseWazim Mohammed Ismail, Jenna A Fernandez, Moritz Binder, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
American Journal of Hematology|June 4, 2026
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell LeukemiaDaniel G Packard, Shaji K Kumar, Angela Dispenzieri, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Blood Advances|April 9, 2026
Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL AmyloidosisMaximilian Johannes Steinhardt, Eli Muchtar, Taxiarchis V Kourelis, et al.
Blood Cancer Journal|June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myelomaBinoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
Haematologica|March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasoneRicardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Pageof 10